Sam Mazin's guest appearances

Sam Mazin

Medsider: Learn from MedTech and HealthTech Experts

The Health Design Podcast

Biotech 2050 Podcast

Sheila Johnson

Peter Diamandis

Michael Bungay Stanier

BJ Miller

Mark Lewis

Robert Gould

Cheryl Janis

Ronald Epstein

Jim Burns

David Berry

David Bates

Jim Sullivan

Tim Sweeney

Tim Miller

Dan Gordon

OwlTail

In this episode of Medsider Radio, we sat down with Dr. Sam Mazin, CEO of RefleXion, a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy. Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's a link to the full interview with Sam if you'd rather read the summary instead.

In this episode of <a href="https://medsider.com/interviews" rel="nofollow" target="_blank">Medsider Radio</a>, we sat down with <a href="https://www.linkedin.com/in/samuelmazin/%20" rel="nofollow" target="_blank">Dr. Sam Mazin</a>, CEO of<a href="https://reflexion.com/" rel="nofollow" target="_blank"> RefleXion,</a> a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy. Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer.  In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to <a href="https://medsider.com/" rel="nofollow" target="_blank">Medsider.com</a> and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a <a href="https://medsider.com/subscribe" rel="nofollow" target="_blank">Medsider premium membership</a>. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of <a href="https://medsider.com/mentors" rel="nofollow" target="_blank">Medsider Mentors</a> at no additional cost. If you’re interested, go to <a href="https://medsider.com/subscribe" rel="nofollow" target="_blank">medsider.com/subscribe</a> to learn more.Lastly, here's a <a href="https://medsider.com/interviews/sam-mazin-reflexion" rel="nofollow" target="_blank">link to the full interview</a> with Sam if you'd rather read the summary instead.

Why Early Risk Retirement is the Best Investment You Can Make: Interview with Dr. Sam Mazin, co-founder and CTO of RefleXion Medical

Samuel Mazin, Ph.D.Founder and Chief Technology OfficerMember, Board of DirectorsSam Mazin, Ph.D., co-founded RefleXion Medical in 2009, where he is the inventor of the company’s core technology. While a postdoctoral researcher in Radiology at Stanford University, Dr. Mazin was selected by the Kauffman Foundation as one of 13 postdocs in the nation to commercialize promising innovations. His prior research at Stanford was focused on the design of a novel X-ray computed tomography (CT) system, resulting in several journal papers and a patent, as well as the Joel Drillings Award from the American Heart Association (AHA). His work on a PET-based algorithm received the prestigious Cum Laude award from the SPIE international medical imaging society. He has been invited to speak about biology-guided radiotherapy by cancer centers worldwide. Dr. Mazin received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and he holds a Ph.D. in Electrical Engineering from Stanford University.Thorsten Melcher, Ph.D.Chief Business OfficerThorsten Melcher, Ph.D., joined RefleXion in July 2019 as chief business officer with over 25 years of experience in biotechnology and pharmaceutical business development. Most recently, Dr. Melcher served as CBO for Xyphos Biosciences, a startup developing next-generation CAR-T products. Previously, he served as senior director of new ventures at J&amp;J, where he championed business development projects focusing on therapeutics in oncology and neuroscience. Dr. Melcher was also vice president at Varian Medical, where he developed a strategy to integrate radiotherapy with diagnostics and therapeutics to improve combination cancer treatment. His other past tenures include co-founding three biotech companies. Dr. Melcher received a Master of Science in Biochemistry from the University of Hannover and he holds a Ph.D. in Molecular Biology from Heidelberg University. He completed postdoctoral research in Molecular Biology at the University of California, San Francisco, and was previously on RefleXion’s scientific advisory board.

Samuel Mazin, Ph.D. Founder and Chief Technology Officer Member, Board of Directors Sam Mazin, Ph.D., co-founded RefleXion Medical in 2009, where he is the inventor of the company’s core technology. While a postdoctoral researcher in Radiology at Stanford University, Dr. Mazin was selected by the Kauffman Foundation as one of 13 postdocs in the nation to commercialize promising innovations. His prior research at Stanford was focused on the design of a novel X-ray computed tomography (CT) system, resulting in several journal papers and a patent, as well as the Joel Drillings Award from the American Heart Association (AHA). His work on a PET-based algorithm received the prestigious Cum Laude award from the SPIE international medical imaging society. He has been invited to speak about biology-guided radiotherapy by cancer centers worldwide. Dr. Mazin received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and he holds a Ph.D. in Electrical Engineering from Stanford University. Thorsten Melcher, Ph.D. Chief Business Officer Thorsten Melcher, Ph.D., joined RefleXion in July 2019 as chief business officer with over 25 years of experience in biotechnology and pharmaceutical business development. Most recently, Dr. Melcher served as CBO for Xyphos Biosciences, a startup developing next-generation CAR-T products. Previously, he served as senior director of new ventures at J&amp;J, where he championed business development projects focusing on therapeutics in oncology and neuroscience. Dr. Melcher was also vice president at Varian Medical, where he developed a strategy to integrate radiotherapy with diagnostics and therapeutics to improve combination cancer treatment. His other past tenures include co-founding three biotech companies. Dr. Melcher received a Master of Science in Biochemistry from the University of Hannover and he holds a Ph.D. in Molecular Biology from Heidelberg University. He completed postdoctoral research in Molecular Biology at the University of California, San Francisco, and was previously on RefleXion’s scientific advisory board.

56. Turning cancer on itself, Sam Mazin, Founder and CTO, Thorsten Melcher, CBO, RefleXion

Sam Mazin is the cofounder and chief technology officer at RefleXion Medical and inventor of the company's core technology. While a Postdoc in Radiology at Stanford University, Sam was selected by the Kauffman Foundation as one of thirteen postdocs in the nation to commercialize promising innovations. His prior research at Stanford was focused on the design of a novel X-ray computed tomography (CT) system, resulting in several journal papers and a patent, as well as the Joel Drillings Award from the American Heart Association.

Sam Mazin  Interview